AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00888225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentric exercise
Description: Concentric exercise treatment at home with three sets of 15 repetitions daily
Study NCT03412825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
Study NCT01983813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHCVRS Intervention
Description: A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk.
Study NCT01983813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Health Record
Description: Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
Study NCT01983813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personal Health Record
Description: Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
Study NCT00816764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV Infusion
Study NCT04388878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07054894
Description: Participants will receive oral ascending doses
Study NCT04388878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo
Study NCT04556188 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Study NCT02443766 — intervention group
Intervention type: OTHER
Intervention: Meditation Retreat
Description: Weeklong retreat which includes meditation and prayer.
Study NCT00695877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5.ENVA.48 HIV-1 vaccine
Description: Recombinant adenovirus serotype 5 HIV-1 vaccine
Study NCT02399787 — intervention group
Intervention type: OTHER
Intervention: blastocyst biopsy
Description: Performed on day 5
Study NCT03549741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg
Description: oral tablets
Study NCT03549741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: oral tablets
Study NCT03549741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline Oral Tablet
Description: oral tablets
Study NCT00605722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib (Tarceva)
Description: 150 mg orally (po) daily.
Study NCT03549741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets
Study NCT03813069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IR3535
Description: The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
Study NCT03813069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin lower dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
Study NCT03813069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin higher dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
Study NCT01101880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01101880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT01101880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01091974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
Study NCT01091974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo for 47 days
Study NCT00272545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normalization of Eating (NOE)
Description: The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
Study NCT01091974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo for 47 days
Study NCT01091974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
Study NCT04511169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital self-help
Description: The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
Study NCT00272545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Treatment as usual will include standard care for a person with an eating disorder.
Study NCT03203590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Navelbine + Carboplatin
Description: The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
Study NCT03203590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
Study NCT00788697 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue-enhanced ultrasound
Description: Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
Study NCT00788697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unenhanced ultrasound
Description: -Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
Study NCT03700632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patch therapy
Description: The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
Study NCT00680953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Study NCT00680953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Study NCT00680953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate sodium hydrate
Description: Oral tablet once a week for 24 months
Study NCT01601470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
Study NCT01601470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
Study NCT05049447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pascoflair
Description: 1 x 2 tablets (single-dose)
Study NCT05049447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x 2 tablets (single-dose)
Study NCT02322411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric Progressive Resistance Oropharyngeal Therapy
Description: Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
Study NCT02322411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory approaches
Study NCT02322411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory approaches
Study NCT02463136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
Study NCT02463136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging w neurofeedback
Description: The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014).
Study NCT00555906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
Study NCT00555906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
Study NCT00555906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
Study NCT01856322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: one tablet 150mg twice daily
Study NCT01856322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice daily
Study NCT01856322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validate assays and shipping methods
Study NCT03251027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IM-SRT
Study NCT03251027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life
Description: Ancillary studies
Study NCT01478464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The hamstring muscle will be massaged with a massage roller for ten minutes.
Study NCT04437173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset Distraction
Description: Patient wears a virtual reality headset during interventional pain procedure
Study NCT03992209 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Usual operating room practice
Study NCT03992209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized care
Description: Hand washing per protocol
Study NCT01830816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules
Study NCT02576886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Camera
Description: All images acquired with the General Electric Discovery 530c
Study NCT02576886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Imaging
Study NCT02319213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 9 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure
Study NCT02319213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 12 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure
Study NCT02319213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with 15 mmHg insufflation
Description: Comparison of intraocular pressure levels at different abdominal pressure
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH4808
Description: Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks
Study NCT02128594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serosorting Intervention
Description: Single session, behavioral intervention
Study NCT03623425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET
Description: a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
Study NCT03623425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET
Description: a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
Study NCT00407173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCV-796
Description: HCV-796 1000mg single dose
Study NCT04655053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal intention
Description: Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
Study NCT04655053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention to initiate the behavior
Description: Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
Study NCT04655053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention to manage the goal preference (avoiding behavior or not)
Description: Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
Study NCT01357980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 750 U intra detrusor injection on Day 1 (single dose)
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH4808
Description: Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH4808
Description: Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks
Study NCT01761513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH4808
Description: Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks
Study NCT02117011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
Study NCT02315222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regenium
Study NCT02315222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02315222 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full Mouth Disinfection
Study NCT02315222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Mouth Disinfection
Study NCT02100293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate 30 mg/kg
Description: Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
Study NCT02486497 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hENT1
Description: hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
Study NCT01866293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184)
Study NCT04468854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin
Description: Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
Study NCT04468854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mannitol formulated for oral administration (capsules)
Study NCT01251237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL0706
Description: Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
Study NCT01525810 — intervention group
Intervention type: DRUG
Intervention: Peginterferon Lambda-1a (BMS-914143)
Description: Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
Study NCT03445208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Crossover administration to abdomen then upper arm
Study NCT01970046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Metformin
Description: * Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks
Study NCT01970046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 50 mg b.i.d/Metformin
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks
Study NCT01970046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 50 mg q.d./Metformin
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks
Study NCT02834260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant OZURDEX
Study NCT00518284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Paclitaxel
Description: Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
Study NCT02100293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Study NCT01357980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra detrusor injection on Day 1 (single dose)